Patents by Inventor Hubo Wang
Hubo Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10562904Abstract: The present application falls within the field of drug synthesis, and in particular, the present application relates to a method for preparing ruxolitinib, and a method for preparing the intermediate and relevant intermediates used. The method comprises reacting a compound of formula II with a compound of formula IV or a salt thereof to obtain a compound of formula III, and then subjecting the compound of formula III to an acyl halogenation reaction, an amidation reaction, and a reaction dehydrating an amide to form a cyano group or removing the protecting group to prepare ruxolitinib. The method has the characteristics of brief steps, a high stereoselectivity, a high utilization ratio of atoms, mild reaction conditions and convenient post treatment. The method avoids using expensive asymmetric reaction catalysts, and is suitable for industrial production.Type: GrantFiled: December 29, 2016Date of Patent: February 18, 2020Assignee: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Inventors: Xiquan Zhang, Aiming Zhang, Zhou Zhou, Leilei Yang, Huadong Yao, Xueyan Zhu, Hubo Wang
-
Patent number: 10292965Abstract: The present invention relates to a nintedanib diethanesulfonate salt A-type crystal represented by formula (II), and also relates to a crystalline composition and pharmaceutical composition comprising the crystal, and preparation method and use thereof. An X-ray powder diffraction spectrum of the nintedanib diethanesulfonate salt A-type crystal of the present invention has a diffraction peak at about 14.64, 18.79, 19.31, 20.11, 21.20, 22.45 and 26.71° when represented via a 2? value. The nintedanib diethanesulfonate salt A-type crystal of the present invention has a stable property, is non-hygroscopic and difficult to degrade, and is particularly suitable for medicine production.Type: GrantFiled: March 11, 2016Date of Patent: May 21, 2019Assignee: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Inventors: Hubo Wang, Xueyan Zhu, Meng Guo, Mingtong Hu, Jiasong Zhang, Jiude Sun
-
Publication number: 20190023712Abstract: The present application falls within the field of drug synthesis, and in particular, the present application relates to a method for preparing ruxolitinib, and a method for preparing the intermediate and relevant intermediates used. The method comprises reacting a compound of formula II with a compound of formula IV or a salt thereof to obtain a compound of formula III, and then subjecting the compound of formula III to an acyl halogenation reaction, an amidation reaction, and a reaction dehydrating an amide to form a cyano group or removing the protecting group to prepare ruxolitinib. The method has the characteristics of brief steps, a high stereoselectivity, a high utilization ratio of atoms, mild reaction conditions and convenient post treatment. The method avoids using expensive asymmetric reaction catalysts, and is suitable for industrial production.Type: ApplicationFiled: December 29, 2016Publication date: January 24, 2019Inventors: Xiquan Zhang, Aiming Zhang, Zhou Zhou, Leilei Yang, Huadong Yao, Xueyan Zhu, Hubo Wang
-
Publication number: 20180064684Abstract: The present invention relates to a nintedanib diethanesulfonate salt A-type crystal represented by formula (II), and also relates to a crystalline composition and pharmaceutical composition comprising the crystal, and preparation method and use thereof. An X-ray powder diffraction spectrum of the nintedanib diethanesulfonate salt A-type crystal of the present invention has a diffraction peak at about 14.64, 18.79, 19.31, 20.11, 21.20, 22.45 and 26.71° when represented via a 2? value. The nintedanib diethanesulfonate salt A-type crystal of the present invention has a stable property, is non-hygroscopic and difficult to degrade, and is particularly suitable for medicine production.Type: ApplicationFiled: March 11, 2016Publication date: March 8, 2018Applicant: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Inventors: Hubo Wang, Xueyan Zhu, Meng Guo, Mingtong Hu, Jiasong Zhang, Jiude Sun
-
Patent number: 8829039Abstract: Disclosed are dihydroindolone compounds which can modulate the activity of protein tyrosine kinases, a method for preparing the same, and pharmaceutical compositions comprising the same. Also disclosed are use of such compounds and pharmaceutical compositions thereof in the treatment and/or prophylaxis of protein tyrosine kinase associated diseases in an organism, particularly in the treatment and/or prophylaxis of tumors and fibroblast proliferation associated diseases.Type: GrantFiled: May 25, 2009Date of Patent: September 9, 2014Assignees: Shanghai Institute of Pharmaceutical Industry, Jiangsu Chiatai Tianqing Pharmaceutical Co., Ltd.Inventors: Zhedong Yuan, Xiaomin Zhang, Hubo Wang, Xueyan Zhu, Hongjiang Xu, Hui Fu, Wei Song
-
Patent number: 8614251Abstract: The invention provides a new crystalline form of agomelatine, preparation and use thereof. The X-ray powder diffraction diagram of the agomelatine crystalline form shows main peaks at the diffraction angles 2? 11.13°, 11.82°, 17.49°, 18.29°, 19.48°, 19.72°, 20.50°, 21.76°, 22.54°, 22.97°, 24.56°, 25.36°, 27.16° and 31.93°. Said new crystalline form is characterized by high purity, stability and good reproducibility, and thus is advantageous for the pharmaceutical formulation. In addition, the stability and solubility of said crystalline form are also superior over the several existing crystalline forms.Type: GrantFiled: March 9, 2010Date of Patent: December 24, 2013Assignee: Les Laboratories ServierInventors: Hanbin Shan, Peng Zhang, Zhedong Yuan, Xudong Jiang, Yu Huang, Hubo Wang, Xufeng Cao, Xingdong Cheng, Xiong Yu
-
Patent number: 8524949Abstract: The present invention relates to a complex of agomelatine and to preparation thereof. The hydrogen halide complex of agomelatine obtained through the present method is more soluble, more stable, and of higher purity than agomelatine itself, making it more suitable to be used in pharmaceutical preparation. Using this method, product of high purity can be obtained through a simple process, without having to incur further complicated steps.Type: GrantFiled: February 26, 2010Date of Patent: September 3, 2013Assignee: Les Laboratories ServierInventors: Hanbin Shan, Peng Zhang, Zhedong Yuan, Xudong Jiang, Yu Huang, Hubo Wang, Xufeng Cao, Xingdong Cheng, Hongjuan Pan, Xiong Yu
-
Publication number: 20120004313Abstract: The invention provides a new crystalline form of agomelatine, preparation and use thereof. The X-ray powder diffraction diagram of the agomelatine crystalline form shows main peaks at the diffraction angles 2? 11.13°, 11.82°, 17.49°, 18.29°, 19.48°, 19.72°, 20.50°, 21.76°, 22.54°, 22.97°, 24.56°, 25.36°, 27.16° and 31.93°. Said new crystalline form is characterized by high purity, stability and good reproducibility, and thus is advantageous for the pharmaceutical formulation. In addition, the stability and solubility of said crystalline form are also superior over the several existing crystalline forms.Type: ApplicationFiled: March 9, 2010Publication date: January 5, 2012Inventors: Hanbin Shan, Peng Zhang, Zhedong Yuan, Xudong Jiang, Yu Huang, Hubo Wang, Xufeng Cao, Xingdong Cheng, Xiong Yu
-
Publication number: 20110313198Abstract: The present invention relates to a complex of agomelatine and to preparation thereof. The hydrogen halide complex of agomelatine obtained through the present method is more soluble, more stable, and of higher purity than agomelatine itself, making it more suitable to be used in pharmaceutical preparation. Using this method, product of high purity can be obtained through a simple process, without having to incur further complicated steps.Type: ApplicationFiled: February 26, 2010Publication date: December 22, 2011Inventors: Peng Zhang, Hanbin Shan, Zhedong Yuan, Xudong Jiang, Yu Huang, Hubo Wang, Xufeng Cao, Xingdong Cheng, Hongjuan Pan, Xiong Yu
-
Publication number: 20110275671Abstract: Disclosed are dihydroindolone compounds which can modulate the activity of protein tyrosine kinases, a method for preparing the same, and pharmaceutical compositions comprising the same. Also disclosed are use of such compounds and pharmaceutical compositions thereof in the treatment and/or prophylaxis of protein tyrosine kinase associated diseases in an organism, particularly in the treatment and/or prophylaxis of tumors and fibroblast proliferation associated diseases.Type: ApplicationFiled: May 25, 2009Publication date: November 10, 2011Applicant: Shanghai Institute of Pharmaceutical IndusrtyInventors: Zhedong Yuan, Xiaomin Zhang, Hubo Wang, Xueyan Zhu, Hongjiang Xu, Hui Fu, Wei Song